G
Genenta Science S.p.A.
Biotechnology: Biological Products (No Diagnostic Substances) company
Key Metrics of Genenta Science S.p.A.
Revenue—FY 2021
Operating income—
Net profit—
Shareholders' equity—
Market cap$30.4MGNTA · $0.63
Competitors10identified
About Genenta Science S.p.A.
Sectors
Company details
- Founded
- 2021
- Listed
- Nasdaq: GNTA (since 2021)
Operational Areas of Genenta Science S.p.A.
Pharmaceuticals & Healthcare›Biotechnology & Vaccines
Company summary
Legal nameGenenta Science S.p.A.
TickerGNTA
ExchangeNasdaq
CountryItaly
SEC CIK0001838716
Listed since2021
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
SectorPharmaceuticals & Healthcare · Biotechnology & Vaccines
Website—
US market & SEC filings
GNTA · Nasdaq · SEC CIK 0001838716
Last price · 25 Oct 2026
$0.63
−1.55%
Market cap$30.4M
P/E—On FY 2021 diluted EPS
Volume36,968
SectorHealth CareBiotechnology: Biological Products (No Diagnostic Substances)
Country · IPOItalyListed 2021
GNTA share price
Premium
Annual results (SEC EDGAR)
Revenue, operating income, net income, EPS, cash flow, assets, liabilities, equity and debt for every year filed with the SEC are part of the premium plan.
Sign in to continue See plans & pricingVendor checks & payment capacity
Sign in with access to company financials to review vendor evidence.
Registered office and contact
Registered office—
GSTIN—
Email—
Website—
Members / shareholders—
Directors and key people
Directors are read from the MGT-7 annual return and AOC-4 signatories.
Competitors of Genenta Science S.p.A.
Competitors10identified
Countries2most in United States
Top competitors by location
| Company | Description | Domain | Founded | Location |
|---|---|---|---|---|
| Part of Vertex Pharmaceuticals. | vrtx.com | 1991 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | gsk.com | 2022 | United Kingdom | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | modernatx.com | 2018 | United States | |
 Becton Dickinson |
Biotechnology & Vaccines · Pharmaceuticals & Healthcare | bd.com | — | United States |
| Part of Illumina. | illumina.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | guardanthealth.com | 2018 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | revvity.com | — | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | exelixis.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | neurocrine.com | 1996 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | biomarin.com | 1999 | United States |
Charges (secured borrowings)
0 registered charges. Lenders, amounts and dates are part of the premium plan.
Statutory auditors
Auditors are read from the AOC-4 auditor's report section.
Business activities and related parties
Principal business activities and related-party transactions are read from MGT-7 and AOC-4 filings.
Filings
No filings on record yet.